scholarly journals Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

BioDrugs ◽  
2020 ◽  
Vol 34 (3) ◽  
pp. 381-393
Author(s):  
Jinmei Su ◽  
Mengtao Li ◽  
Lan He ◽  
Dongbao Zhao ◽  
Weiguo Wan ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document